Literature DB >> 6614070

A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure.

A V Moorthy, M Rosenblum, R Rajaram, A L Shug.   

Abstract

We studied plasma, dialysate, and muscle carnitine levels in patients with stable chronic renal failure on hemodialysis, and intermittent peritoneal, or continuous ambulatory peritoneal dialysis (CAPD). In patients on hemodialysis, plasma carnitine levels fell from 46.2 +/- 4.5 mumol/l (mean +/- SEM) to 18.8 +/- 2.7 mumol/l immediately after the procedure (p less than 0.001). Depletion of muscle carnitine was found after hemodialysis (1,518 +/- 273 nmol/g wet weight of tissue) compared to normal levels of 5,230.5 +/- 142.7 nmol/g tissue (p less than 0.01). However, the plasma and muscle carnitine levels remained in the normal range in patients on intermittent peritoneal dialysis and CAPD. We postulate that the rapid decline in plasma levels of carnitine caused by hemodialysis initiates unilateral transport of the compound from muscle to the plasma, thus depleting the skeletal muscle stores of carnitine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6614070     DOI: 10.1159/000166711

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  13 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

3.  Continuous ambulatory peritoneal dialysis (CAPD) adequacy influences serum free carnitine level.

Authors:  A E Grzegorzewska; I Mariak; A Dobrowolska-Zachwieja
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Influence of sex and chronic haemodialysis treatment on total, free and acyl carnitine concentrations in human serum.

Authors:  A S Alhomida; S H Sobki; M H al-Sulaiman; A A al-Khader
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

5.  [Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function].

Authors:  M Leschke; K W Rumpf; T Eisenhauer; K Becker; U Bock; F Scheler
Journal:  Klin Wochenschr       Date:  1984-03-15

6.  Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.

Authors:  W A Gahl; I Bernardini; M Dalakas; W B Rizzo; G S Harper; J M Hoeg; O Hurko; J Bernar
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 7.  Nutritional management of children with chronic renal failure. Summary of the task force on nutritional management of children with chronic renal failure.

Authors:  S Hellerstein; M A Holliday; W E Grupe; R N Fine; R S Fennell; R W Chesney; J C Chan
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

8.  Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients.

Authors:  Celalettin Koşan; Lale Sever; Nil Arisoy; Salim Calişkan; Ozgür Kasapçopur
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

Review 9.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  The role of carnitine in maintenance dialysis therapy.

Authors:  Heather A Morgans; Vimal Chadha; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.